Menu
Back to Journals » OncoTargets and Therapy » Volume 6
The emerging role of RNA polymerase I transcription machinery in human malignancy: a clinical perspective
Authors Montanaro L, Treré D, Derenzini M
Received 30 April 2013
Accepted for publication 1 June 2013
Published 19 July 2013 Volume 2013:6 Pages 909—916
DOI https://doi.org/10.2147/OTT.S36627
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Lorenzo Montanaro, Davide Treré, Massimo Derenzini
Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy
Abstract: Ribosome biogenesis – the complex and highly coordinated cellular process leading to the production of ribosomes – is strictly dependent on the activity of RNA polymerase I (Pol I) transcriptional machinery. Pol I activity is continually increased in proliferating cells to sustain the increased demand for ribosome production and protein synthesis, which are necessary for appropriate cell growth and division. The integrity of the process of ribosome biogenesis represents an important sensor of cellular stress: when this process is altered, a tumor suppressor response is triggered, which leads to proliferative arrest. The present review focuses on the possible implications of Pol I targeting in the treatment of human malignancies.
Keywords: RNA polymerase I inhibitors, ribosome biogenesis, cell cycle control, cancer, Pol I
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.